Lymphoma and leukemia cell therapy by humanized antibodies

Forschungsstelle

INNOSUISSE

Projektnummer

46049.1 IP-LS

Projekttitel

Lymphoma and leukemia cell therapy by humanized antibodies

Projekttitel Englisch

Lymphoma and leukemia cell therapy by humanized antibodies

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-	-

Kategorie	Text
Kurzbeschreibung (Deutsch)	Lymphoma and leukemia cell therapy by humanized antibodies
Kurzbeschreibung (Englisch)	Lymphoma and leukemia cell therapy by humanized antibodies
Abstract (Deutsch)	Abologix developed humanized monoclonal antibodies (mAbs) directed against the adhesion molecule C (JAM-C), a novel cancer target expressed on multiple B-cell lymphomas and leukemia cells. Classical treatment often fails due to resistance, but JAM-C still can be targeted and used for rescue.